{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:14:32Z","timestamp":1791112472602,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jacl.2014.03.006","type":"journal-article","created":{"date-parts":[[2014,3,30]],"date-time":"2014-03-30T01:00:26Z","timestamp":1396141226000},"page":"448-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dramatic lowering of very high Lp(a) in response to niacin"],"prefix":"10.1016","volume":"8","author":[{"given":"Min","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Saeedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon W.","family":"Rabkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Frohlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2014.03.006_bib1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.03.006_bib2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/heartjnl-2013-304902","article-title":"Lipoprotein(a): the underestimated cardiovascular risk factor","volume":"100","author":"Thompson","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacl.2014.03.006_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosissup.2012.10.036","article-title":"Nicotinic acid as a lipid-modifying drug\u2013a review","volume":"14","author":"Julius","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2014.03.006_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/HCO.0b013e32832ac21a","article-title":"Lipoprotein a: where are we now?","volume":"24","author":"Tziomalos","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacl.2014.03.006_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/heart.89.8.893","article-title":"Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia","volume":"89","author":"van Wissen","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.jacl.2014.03.006_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1007079223546","article-title":"Evaluation of a new apolipoprotein(a) isoform-independent assay for serum lipoprotein(a)","volume":"207","author":"Dembinski","year":"2000","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jacl.2014.03.006_bib7","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2014.03.006_bib8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.296.11.1363","article-title":"Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women","volume":"296","author":"Suk Danik","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2014.03.006_bib9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.03.006_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2014.03.006_bib11","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2013.09.003","article-title":"Lipoprotein(a), cardiovascular disease, and contemporary management","volume":"88","author":"Jacobson","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2014.03.006_bib12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1331\/JAPhA.2008.07109","article-title":"Practical management of dyslipidemia with elevated lipoprotein(a)","volume":"48","author":"Riche","year":"2008","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.jacl.2014.03.006_bib13","first-page":"83","article-title":"Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials","volume":"154","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2014.03.006_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","article-title":"Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis","volume":"210","author":"Bruckert","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2014.03.006_bib15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2014.03.006_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacl.2014.03.006_bib17","doi-asserted-by":"crossref","first-page":"44B","DOI":"10.1016\/j.amjcard.2008.02.031","article-title":"Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations","volume":"101","author":"Scanu","year":"2008","journal-title":"J Am Cardiol"},{"key":"10.1016\/j.jacl.2014.03.006_bib18","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2014.03.006_bib19","series-title":"Lipoprotein(a)","first-page":"151","article-title":"Incidence of Lp(a) among populations","author":"Dahlen","year":"1990"},{"key":"10.1016\/j.jacl.2014.03.006_bib20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/clinchem\/40.4.571","article-title":"Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula","volume":"40","author":"Li","year":"1994","journal-title":"Clin Chem"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414002098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414002098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T01:18:41Z","timestamp":1597627121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287414002098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1933287414002098"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2014.03.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dramatic lowering of very high Lp(a) in response to niacin","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2014.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}